Direct Oral Anticoagulants

ApprovedSmall molecule

Direct Oral Anticoagulants is one of 85 small molecule programs targeting Venous thrombosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThrombosisActive, not recruiting

Pulmonary EmbolismActive, not recruiting

Atrial FibrillationActive, not recruiting

Venous ThrombosisPreclinical

Active, not recruiting

Pulmonary EmbolismPhase 3

Active, not recruiting

Atrial FibrillationApproved

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Direct Oral Anticoagulants

Bayer

Approved

2 2

Rituxan

Imbruvica

1 4

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 5

Direct Anticoagulant

Bayer

Preclinical

1 6

Calcium

Eli Lilly

Preclinical

1 7

Magnesium SO4

HHospital de Base

Preclinical

2 8

Anticoagulation

HHospital Álvaro Cunqueiro

Preclinical

1 9

Bupivacain

IIstanbul University

Preclinical

1 10

Standard BP Control

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Complication

NCT05198960

Q1 2031

Post-ApprovalRecruiting

Atrial Fibrillation

NCT04700826

Clinical

Trials by Indication[1]

Atrial Fibrillation2 trials

Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation

Recruiting·UUniversity of Birmingham·Phase 4·NCT04700826·3,000 enrolled

Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT03596502·402,764 enrolled

Complication1 trial

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Recruiting·UUniversity Hospital, Brest·Phase 3·NCT05198960·1,308 enrolled

Pulmonary Embolism1 trial

STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism

Unknown status·UUniversity of Birmingham·Phase 3·NCT04727437·1,466 enrolled

Venous thrombosis1 trial

DOAC in Unusual Site Venous Thrombosis

Completed·—··NCT03778502·358 enrolled

Rivaroxaban1 trial

Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort

Completed· Bayer logo

Bayer··NCT04979780·3,708 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Direct Oral Anticoagulants. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Direct Oral Anticoagulants compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Direct Oral Anticoagulants. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Bayer

Direct Oral Anticoagulants

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2031

Trials by Indication[1]

Atrial Fibrillation2 trials

Complication1 trial

Pulmonary Embolism1 trial

Venous thrombosis1 trial

Rivaroxaban1 trial

References

Drug Info

Quick Facts

Related News